Credit Suisse’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Credit Suisse’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-55,593	Closed	-$4.18M	–	4529
2022 Q2	$4.18M	Sell	55,593 -805,813	-94%	-$35.8M	﹤0.01%	1405
2022 Q1	$23.1M	Sell	861,406 -669	-0.1%	-$22.5K	0.02%	707
2021 Q4	$41.1M	Sell	862,075 -4,748	-0.5%	-$212K	0.02%	736
2021 Q3	$57.6M	Buy	866,823 +4,425	+0.5%	+$315K	0.03%	589
2021 Q2	$67.3M	Buy	862,398 +53,636	+7%	+$3.96M	0.04%	538
2021 Q1	$76.5M	Sell	808,762 -2,600	-0.3%	-$309K	0.04%	530
2020 Q4	$98.9M	Buy	811,362 +255,604	+46%	+$28M	0.05%	427
2020 Q3	$48.6M	Sell	555,758 -1,171	-0.2%	-$81.6K	0.03%	620
2020 Q2	$36M	Buy	556,929 +193,988	+53%	+$11.2M	0.03%	677
2020 Q1	$16.2M	Buy	362,941 +155,259	+75%	+$8.25M	0.01%	934
2019 Q4	$12.9M	Buy	+207,682	New	+$9.88M	0.01%	1266

Credit Suisse's TPTX Position: Q3 2022 in Review

Credit Suisse sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 55,593 shares — an estimated $4.18M sold.

Credit Suisse first reported a position in TPTX in Q4 2019 and held it in 11 quarters. The position peaked at $98.9M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Credit Suisse reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 55,593 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $4.18M.
Credit Suisse first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
Credit Suisse's Turning Point Therapeutics, Inc. Common Stock position peaked at $98.9M in Q4 2020.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.